The short answer
Yohimbe products need review before use with clonidine because their yohimbine content may oppose clonidine’s blood-pressure effect. Direct human evidence comes from purified yohimbine, not a standardized trial of every bark extract.
What this answer covers
Oral Pausinystalia johimbe/yohimbe bark preparations with oral clonidine. The trial used isolated yohimbine hydrochloride; botanical content is an explicit uncertainty.
- Supplement or preparation
- yohimbe
- Medication ingredient
- clonidine
Why is the yohimbine content important?
A human experiment found that purified yohimbine reversed clonidine-related lowering of systolic pressure. Yohimbe bark can supply that substance, but a supplement’s exposure depends on its actual content. The concern is therefore conditional on the preparation, not a measured response to every brand.
What does the research not establish?
The experiment used single known doses in healthy volunteers. It does not tell us which bark product or amount would produce the same result, or how often long-term users would develop a clinical problem. An unspecified side-effect warning is less useful than naming the possible opposing pressure effect.
Can the label be trusted to predict exposure?
NCCIH describes substantial variation and labeling problems in yohimbe supplements. Bring the actual bottle to a pharmacist. A “natural” description or missing yohimbine amount cannot establish that a product is free of this concern.
What is the practical next step?
Review yohimbe before adding it to clonidine treatment. The sources do not establish that taking the products hours apart removes the problem. Do not change clonidine yourself in response to a supplement warning.
Evidence and practical considerations
Physiologic interactions
Purified yohimbine directly opposed acute clonidine effects in humans; applying this concern to yohimbe bark depends on its yohimbine content.
- Exact scope
- Oral Pausinystalia johimbe/yohimbe bark preparations with oral clonidine. The trial used isolated yohimbine hydrochloride; botanical content is an explicit uncertainty. with Clonidine, RxCUI 2599, IN. The inspected oral immediate-release clonidine hydrochloride label explicitly identifies its clonidine free-base equivalent. That salt-to-active-ingredient bridge is restricted to the labeled oral formulation; patch, epidural and extended-release regimens are not assigned the same exposure automatically.
- Medication form and route
- oral
What remains uncertain
- Botanical content unquantified; no direct bark-clonidine clinical trial or long-term estimate.
Factors that may matter: exact product and dose; baseline blood pressure; other medicines.
Read the supporting source summaries
Source 1: original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy volunteers in a double-blind crossover experiment.
Yohimbine reversed the clonidine-associated systolic-pressure reduction, reduced alertness and prolonged light-reflex recovery.
How this applies: Direct acute coadministration of the named active ingredients as hydrochloride salts. Applying the measured yohimbine exposure to bark products requires a content qualification.
Original abstract inspected. No long-term hypertension outcomes, product-specific bark doses, or clonidine absorption measurements. The abstract does not explicitly state the administration route; full-text methods still require verification before clinical publication.
Source 2: government botanical reference
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering yohimbe supplements.
Identifies blood-pressure and other serious safety concerns; the amount of yohimbine can vary and labeling may be inaccurate.
How this applies: Purified yohimbine and variable-content bark supplements are different exposures; no bark dose is inferred from the acute trial.
General botanical safety reference rather than a controlled clonidine interaction trial.
Source 3: regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release clonidine.
Describes blood-pressure lowering, sedation, interactions with other sedating drugs, and potentially severe rebound hypertension after abrupt withdrawal.
How this applies: Defines medication context and prevents an unsupported recommendation to stop clonidine.
Does not directly test the botanical combinations in this batch. The free-base bridge is explicit in Description.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original article drafted after source checks. Exact preparation, route, contrary evidence and claim limitations recorded for review. | |
| Research summary published |
Article revision: d81e71e9b1d5e189
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.